Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.

doi:10.2174/157489209787002461

Back to search

Article

Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.

Recent patents on anti-cancer drug discovery - 1 Jan 2009

Wong Kwong-Kwok

Abstract excerpt

The Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) pathway mediates cellular responses to different growth signals and is frequently deregulated in cancer. There are three Raf kinases-A-Raf, B-Raf, and C-Raf; however, only B-Raf is frequently mutated in various cancers. The most common B...

Topics

Animals
Antineoplastic Agents
Clinical Trials as Topic
Extracellular Signal-Regulated MAP Kinases
Humans
Mitogen-Activated Protein Kinase Kinases
Mutation
Proto-Oncogene Proteins B-raf
Signal Transduction
raf Kinases
ras Proteins

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.